Eurepa V 1 0 2mg Tablet belongs to the therapeutic classification of Antidiabetic Agents The primary composition for this medicine is Repaglinide 1 MG Voglibose 0 2 MG

Before taking this medication tell your doctor or healthcare professional if you are allergic to Repaglinide and voglibose or have other allergies This product may contain inActive ingredients which can cause allergic reactions or other problems Eurepa V 1 0 2 Tablet 10 s should not be stopped even if you feel better without consulting your doctor as sugar level keeps changing If you stop taking Eurepa V 1 0 2 Tablet 10 s abruptly it may increase your sugar levels which could further increase the risk of eyesight loss retinopathy kidney nephropathy and nerve damage neuropathy Eurepa V 1 0 2 Tablet 10 s should not be taken if you have type 1 diabetes mellitus severe kidney or liver disease During pregnancy lactation this medication should be used only when clearly needed Discuss the risks and benefits with your doctor